BMO Capital Rates ICON Public (ICLR) buy, $187 Price Target

Analyst Sean Dodge keeps an upbeat stance on ICLR as clinical trial demand stays steady across global healthcare markets, a 8.10% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 2:01 PM EDT · Updated Jun 30, 2026, 6:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BMO Capital rated ICON Public Limited Company ($ICLR) "buy" with a $187 price target on June 25, 2026.

Since the rating, $ICLR is up 7.5% after 1 week, up 4.9% after 1 month and up 5.7% to date (from the $160.96 close on Jun 25, 2026).

ICLR ICON Public Limited Company

$170.18 -9.80% year to date

Daily close · Oct 16, 2026

Key Points

On June 25, 2026, BMO Capital analyst Sean Dodge reiterated a buy rating on ICON Public Limited Company (NASDAQ:ICLR) alongside a price target of $187.00.
BMO Capital's $187 price target implies 8.10% upside from ICON Public Limited Company's ($ICLR) current $172.99 share price.
The broader Wall Street outlook features 16 analyst opinions pointing toward a consensus buy recommendation and a mean price target of $185.25.
ICON trades near $172.99, staying comfortably above its 200-day moving average of $147.20 while managing a forward P/E ratio of 14.37.

Get $ICLR trade alerts by text

We text you when insiders, Congress or big funds trade $ICLR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ICON Public Limited Company alert may contain errors. Disclosures

BMO Capital Reaffirms Outlook on ICLR

On June 25, 2026, BMO Capital analyst Sean Dodge kept a buy rating on ICON Public Limited Company (NASDAQ:ICLR), maintaining a price target of $187.00 for the clinical research provider. The updated view arrives as part of an active stretch of research notes from major financial firms tracking the Dublin-headquartered company, reflecting steady sentiment toward the outsourced medical development sector.

Analyst rating track record

BMO Capital vs. the S&P 500

YTD return +8.75% hypothetical

All-time return +3.60% S&P 500 +25.77%

vs. S&P 500 -22.17% behind the index

Hypothetical returns from BMO Capital's disclosed trades, not real profit or advice. How we model this.

Wall Street Analyst Landscape

Other major research houses have also reviewed their positions on the healthcare stock through the summer and autumn. On June 25, 2026, Barclays maintained an equal-weight rating while lifting its target to $175.00 from $160.00. Mizuho followed on June 26, 2026, keeping an outperform rating and a $190.00 target. Later in the month on June 30, 2026, Truist Securities upgraded the shares to a buy with a $207.00 price target, later nudging that target to $209.00 on July 31, 2026. Citigroup has also adjusted its stance across multiple dates, maintaining a neutral rating on September 18, 2026, while setting a $175.00 target after earlier updates at $180.00 and $165.00. Across the broader group, 16 analysts contribute to a consensus buy recommendation with a mean target price of $185.25.

ICLR Share Performance and Valuation

Trading around $172.99, ICON shares sit comfortably above key moving averages, including the 50-day moving average of $167.30 and the 200-day line of $147.20. The company carries a market capitalization of $13.08 billion and a forward P/E ratio of 14.37, paired with a PEG ratio of 0.50. The 52-week trading span reaches from a low of $66.57 up to a peak of $203.91, showing a recovery over recent reporting periods.

Clinical Research Operations in Dublin

Based in Dublin, Ireland, ICON Public Limited Company operates as a clinical research organization that assists pharmaceutical, biotechnology, and medical device companies with drug development and trial management. The firm handles everything from early compound selection to sprawling Phase I-IV clinical studies, supporting clients with laboratory services, bioanalytical testing, and data solutions across international markets.

Upcoming Financial Milestones

Market participants continue to monitor operational updates and cost structures across the contract research space. Investors will look toward the company's next earnings release scheduled for October 21, 2026, to gauge how well top-line growth matches up against forward valuation metrics.

12-month forecast